Table 2.
Baseline Cardiovascular Structure and Function
| Placebo (n=25) | Sildenafil (n=23) | p | |
|---|---|---|---|
| Heart rate (bpm) | 61 (56, 75) | 62 (58, 75) | 0.8 |
| SBP (mmHg) | 122 (108, 128) | 118 (110, 128) | 0.8 |
| DBP (mmHg) | 64 (62, 70) | 70 (62, 74) | 0.15 |
| LV structure and function | |||
| EDV (ml, n=23/21) | 126 (113, 137) | 114 (101, 128) | 0.18 |
| LV mass (gm, n=22/18) | 167 (153, 225) | 167 (123, 207) | 0.4 |
| E velocity (cm/s, n=25/22) | 70 (60, 100) | 70 (60, 90) | 0.6 |
| DT (ms, n=24/22) | 215 (202, 251) | 221 (190, 251) | 0.8 |
| E/A ratio (n=23/20) | 1.0 (0.8, 2.1) | 1.1 (0.8, 1.3) | 0.7 |
| E′ (cm/s) | 6.5 (5.5, 7.0) | 6.0 (5.0, 6.5) | 0.2 |
| E/e′ ratio (n=25/22) | 11.7 (9.3, 15.0) | 12.5 (9.3, 20.0) | 0.6 |
| EF (%, n=24/23) | 60 (55, 60) | 60 (55, 60) | 0.6 |
| PWR/EDV (mmHg/sec, n=23/21) | 327 (277, 365) | 359 (319, 380) | 0.19 |
| SW/EDV (mmHg, n=23/21) | 50.7 (46.5, 55.2) | 54.2 (47.3, 56.8) | 0.3 |
| Vascular Function | |||
| Ea (mmHg/ml, n=24/21) | 1.5 (1.2, 1.7) | 1.7 (1.6, 1.9) | 0.07 |
| RHI (n=19/14) | 1.9 (1.6, 2.3) | 1.9 (1.5, 2.1) | 0.6 |
| ED (%) | 53 | 64 | 0.5 |
| SVR (DSC, n=24/21) | 1417 (1245, 1700) | 1688 (1385, 1828) | 0.11 |
| TAC (ml/mmHg, n=22/20) | 1.69 (1.40, 2.43) | 1.71 (1.33, 1.99) | 0.7 |
| cSBP (mmHg, n=23/22) | 110 (100, 121) | 109 (99, 118) | 0.7 |
| cAIx (%, n=23/22) | 24 (17, 29) | 24.5 (17, 29) | 0.98 |
| PASP (mmHg, n=19/11) | 30 (28, 43.4) | 28 (26.2, 41) | 0.3 |
| Exercise Capacity | |||
| Peak VO2 (ml/min/kg) | 12.6 (11.1, 14.3) | 11.6 (10.1, 15.7) | 0.97 |
| Peak RER | 1.07 (10.4, 1.11) | 1.09 (1.03, 1.17) | 0.4 |
| Exercise Hemodynamics and Reserve | |||
| ΔHR, low (bpm) | 13 (9, 18) | 16 (9, 18) | 0.8 |
| ΔHR, peak (bpm) | 47 (34, 53) | 52 (34, 70) | 0.13 |
| ΔSBP, low (mmHg) | 10 (2, 16) | 14 (6, 18) | 0.4 |
| ΔSBP, peak (mmHg) | 38 (28, 56) | 34 (22, 58) | 0.5 |
| ΔDBP, low (mmHg) | 2 (0, 4) | 0 (−2, 4) | 0.4 |
| ΔDBP, peak (mmHg) | 2 (−6, 8) | 6 (−2, 10) | 0.2 |
| ΔEF, low (%, n=23/23) | 5 (0, 5) | 0 (0, 5) | 0.06 |
| ΔEF, peak (%, n=21/21) | 10 (5, 10) | 5 (5, 10) | 0.19 |
Column 1 parentheses indicate number of placebo/sildenafil subjects with available data for each parameter; if no numbers are presented there was no data missing. P values are not adjusted for multiple comparisons.